A patient from the UK is currently testing IBDoc® and is writing about his experience on his blog. He started the test last October and is trying this new tool to monitor his Crohn’s Disease during one year. Have a look at his blog posts here
Blog Archives
For the second year, Boussias Communications and Health Daily organized the Healthcare Business Awards 2017 in Greece. The award is meant to showcase and reward innovative healthcare actions. This year the AbbVie Greece received the Gold Award in the Health Innovation category. Together with BÜHLMANN Laboratories AG and the home care provider PCC Hellas AbbVie implemented IBDoc® into their Care Programm for patients suffering
In September we received regulatory approval to expand the list of supported smartphones for IBDoc®. Like for the previous approvals, we used our established thorough validation control to add 12 additional models. Since each smartphone model differs in camera and processor type, which relates to differences in measurement we always need to make sure that the supported
IBDoc® has now been on the market for over 2 years and it is transforming the way IBD patients manage their disease. IBDoc® is used by over a thousand patients in more than 15 countries and we now support 20 languages with Hebrew as the latest addition. BÜHLMANN as the only calprotectin company has been able
Calprotectin: The Key to a Successful Treatment Pathway for IBD What is Inflammatory Bowel Disease? Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most
Continue Reading →
In December we received regulatory approval to expand the list of supported smartphones for IBDoc. To achieve this we established a thorough validation control to be able to include new smartphones. Since each smartphone model differs in camera and processor type, which relates to differences in measurement we always need to make sure that the supported
Interview with Dr. Christian Reinhard at UEGW 2016 about the first 18 months of market experience with IBDoc® At this year’s UEGW in Vienna, Dr. Christian Reinhard presented data collected from the first 18 months of market expirience with IBDoc®. In the biomarker session on Tuesday 18th of October the IBDoc® product manager at BÜHLMANN Laboratories
At the last European Crohn’s and Colitis Congress in Amsterdam we took the chance to record a video of our congress presence as well as a two interviews: One with an IBD Nurse, Anita Beyer, from the General Hospital in Vienna (AKH), who has been using IBDoc® since over one year and another interview with
At this year’s ECCO we took the chance to record an interview with Julia Edin, an IBD Patient from Oslo, who has been using IBDoc® for over a year:
At this year’s ECCO we took the chance to record an interview with Anita Beyer, an IBD Nurse in Vienna, who has been using IBDoc® for over a year: